C-reactive protein provides independent prognostic information on short- and long-term mortality in patients with non-st elevation acute coronary syndrome: Reply  by James, Stefan & Wallentin, Lars
Moreover, the researchers state that “the levels of troponin and
CRP provide important, different and complementary prognostic
information. . . . The combination of both markers allows the best
prediction of mortality.” We do not share such enthusiastic
comment. Table 4 in the James et al. (1) study (“Mortality at 30
Days in Relation to Quartiles of Troponin T and CRP”) shows
that patients with the highest values of troponin T (0.47 g/l)
and CRP (9.62 mg/l) had a 9.1% death rate, which is not very
different, on clinical grounds, from the 7.4% death rate of all
patients included in the highest troponin T quartile (the clinical
relevance of the 3.6% mortality in the first CRP quartile being
affected by the small number of patients in that subgroup, n 
250). In contrast, in the lowest troponin T quartile (0.01 g/l),
the death rate was 1.4% in patients with the highest CRP values
(9.62 mg/l), not dissimilar from the 1.1% death rate of all
patients with0.01 g/l troponin levels. From these data it seems
that CRP does not provide any additional important prognostic
information to the simple knowledge of troponin T values.
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REPLY
We appreciate the interest of Drs. De Servi and Mazzone in our
recently published study (1). The relation between C-reactive
protein (CRP) elevation and subsequent mortality in our study is
very consistent with the results of numerous previous studies
(2–4). In contrast to earlier trials, our study from the GUSTO IV
investigation included a sufficiently large number of patients to
allow the evaluation of subsequent death and myocardial infarction
(MI) separately. It is correct that patients with a CRP level above
1.84 mg/l, paradoxically, had a lower probability of MI at 30 days’
follow-up than did patients with a CRP level 1.84 mg/l. This
statistical significance is, however, dependent on the chosen cutoff
for CRP. A more correct interpretation would be that no relation
exists between levels of CRP and the incidence of MI at 30 days’
follow-up in this selected patient population, as several previous
studies have suggested (3,4).
Levels of CRP and troponin T are correlated (Spearman rank
correlation coefficient 0.24, p  0.001), and a large part of the
inflammatory response seems to be a result of myocardial necrosis
(5). Interestingly, in a multiple linear regression analysis, a history
of MI (10 days before admission), heart failure, levels of
troponin T, and diabetes mellitus were factors with the strongest
independent relation to admission levels of CRP (data not shown).
Thus, CRP elevation at admission in patients with acute coronary
syndromes may be explained by different processes, among them
myocardial remodeling and fibrosis (6) and not solely by the acute
myocardial damage.
The 9.1% mortality at 30 days for patients with troponin T in
the top quartile (0.47 g/l) together with CRP in the top
quartile (9.62 mg/l) may not seem to be extremely different from
the 7.4% mortality for all patients with troponin T above 0.47 g/l
(regardless of CRP levels). Still, the addition of CRP elevation
resulted in a 1.7% absolute increase in 30-day mortality with an
independent contribution. For long-term mortality, CRP provided
an even better prediction, with 17.8% mortality for patients with
CRP and troponin T in the top quartiles (Table 1) as compared to
13.3% for all patients with troponin T in the top quartile. In a
multiple regression analysis, CRP was an independent predictor of
one-year mortality after correction for a large number of significant
predictors, including a history of heart failure on admission as well
as heart rate and elevated levels of troponin T and N-terminal pro
brain natriuretic peptide (7). Hence, CRP provides an independent
prediction on long-term mortality beyond a history of, and clinical
signs of, heart failure as well as biochemical markers indicating
myocardial damage and dysfunction. The mechanisms responsible
for this increased mortality needs to be further investigated (7).
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Table 1. Mortality at One Year in Relation to Quartiles of Troponin T and CRP
CRP, mg/l
Troponin T (g/l)
p
Value*<0.01 0.01–0.12 0.12–0.47 >0.47
1.84 1.7 (11) 5.8 (28) 7.7 (30) 8.8 (22)  0.001
1.84–3.96 5.1 (27) 5.6 (25) 5.1 (23) 11.6 (41)  0.001
3.96–9.62 3.2 (14) 7.7 (30) 8.4 (40) 10.2 (48)  0.001
9.62 6.1 (22) 13.8 (43) 14.1 (60) 17.8 (121)  0.001
p value* 0.01*  0.001*  0.001*  0.001*
Figures are shown as percentages; number of patients are shown in parentheses. *Chi-square linear-by-linear association.
CRP  C-reactive protein.
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